氨酸通过在Limosilactobacillus mucosae中通过增强的氨酸代谢促进精子积累来缓解结肠屏障功能障碍
Xingjian Zhou1, Qian Xu1, Xiangyu Zhang1
1State Key Laboratory of Animal Nutrition and Feeding, College of Animal Science and Technology, China Agricultural University, Beijing, China.
mSystems
|April 2, 2024
概括
食氨酸补充剂可以通过增强微生物精子生产来恢复肠道屏障的完整性. 这一过程涉及特定的细菌,如Limosilactobacillus mucosae,以及它们的氨酸代谢,有利于肠道健康.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 营养科学 营养科学
背景情况:
- 缺乏食纤维会破坏肠道屏障和益生菌平衡.
- 素在拯救这些缺陷中的作用在很大程度上是未知的.
- 微生物聚胺,如精子,可以支持肠道健康.
研究的目的:
- 为了研究外源性粘素如何维持肠道屏障功能.
- 阐明粘素影响微生物代谢物和肠道健康的机制.
- 为了识别特定的微生物和涉及的代谢途径.
主要方法:
- 在体内使用食素补充剂的研究.
- 在体外模型研究微生物与粘真菌的相互作用.
- 特定细菌菌株及其代谢活动的识别.
- 分析聚胺生产及其对肠道屏障标记物的影响.
主要成果:
- 食粘素减轻了纤维剥夺引起的结肠壁缺陷.
- 氨酸补充剂增加了微生物衍生精子的产量,与增加的乳杆菌丰度有关.
- Limosilactobacillus mucosae被确定为一个关键的精子生产者,特别是在粘附于粘真菌时.
- 来自L.L.的细菌上游物. 粘膜通过精氨酸和氨酸代谢增强了屏障功能.
结论:
- 氨酸补充剂可以通过调节微生物氨酸代谢来恢复肠道屏障的完整性.
- 微生物衍生精氨酸在调解粘素对肠道屏障的有益作用方面发挥着至关重要的作用.
- 这突显了一种新的机制,它将饮食中的粘素,微生物代谢物和宿主肠道健康联系在一起.
更多相关视频
相关概念视频
Mucosal Barrier of the Stomach
649
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
649
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
479
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
479
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
409
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
409
Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
428
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
428


